1	Two	_	CD	_	_	3	NMOD	_	_
2	rival	_	JJ	_	_	3	NMOD	_	_
3	bidders	_	NNS	_	_	7	SBJ	_	_
4	for	_	IN	_	_	3	NMOD	_	_
5	Connaught	_	NNP	_	_	6	NAME	_	_
6	BioSciences	_	NNPS	_	_	4	PMOD	_	_
7	extended	_	VBD	_	_	0	ROOT	_	_
8	their	_	PRP$	_	_	9	NMOD	_	_
9	offers	_	NNS	_	_	7	OBJ	_	_
10	to	_	TO	_	_	9	NMOD	_	_
11	acquire	_	VB	_	_	10	IM	_	_
12	the	_	DT	_	_	15	NMOD	_	_
13	Toronto-based	_	JJ	_	_	15	NMOD	_	_
14	vaccine	_	NN	_	_	15	NMOD	_	_
15	manufacturer	_	NN	_	_	11	OBJ	_	_
16	Friday	_	NNP	_	_	7	TMP	_	_
17	.	_	.	_	_	7	P	_	_

1	Institut	_	NNP	_	_	2	NAME	_	_
2	Merieux	_	NNP	_	_	25	SBJ	_	_
3	S.A.	_	NNP	_	_	2	POSTHON	_	_
4	,	_	,	_	_	2	P	_	_
5	which	_	WDT	_	_	6	SBJ	_	_
6	offered	_	VBD	_	_	2	NMOD	_	_
7	942	_	CD	_	_	8	DEP	_	_
8	million	_	CD	_	_	10	NMOD	_	_
9	Canadian	_	JJ	_	_	10	NMOD	_	_
10	dollars	_	NNS	_	_	6	OBJ	_	_
11	(	_	(	_	_	12	P	_	_
12	US$	_	$	_	_	10	PRN	_	_
13	801.2	_	CD	_	_	12	DEP	_	_
14	million	_	CD	_	_	12	DEP	_	_
15	)	_	)	_	_	12	P	_	_
16	,	_	,	_	_	10	P	_	_
17	or	_	CC	_	_	10	COORD	_	_
18	C$	_	$	_	_	17	CONJ	_	_
19	37	_	CD	_	_	18	NMOD	_	_
20	a	_	DT	_	_	21	NMOD	_	_
21	share	_	NN	_	_	18	ADV	_	_
22	for	_	IN	_	_	6	ADV	_	_
23	Connaught	_	NNP	_	_	22	PMOD	_	_
24	,	_	,	_	_	2	P	_	_
25	said	_	VBD	_	_	0	ROOT	_	_
26	it	_	PRP	_	_	27	SBJ	_	_
27	would	_	MD	_	_	25	OBJ	_	_
28	extend	_	VB	_	_	27	VC	_	_
29	its	_	PRP$	_	_	30	NMOD	_	_
30	bid	_	NN	_	_	28	OBJ	_	_
31	,	_	,	_	_	30	P	_	_
32	due	_	JJ	_	_	30	APPO	_	_
33	to	_	TO	_	_	32	AMOD	_	_
34	expire	_	VB	_	_	33	IM	_	_
35	last	_	JJ	_	_	36	NMOD	_	_
36	Thursday	_	NNP	_	_	34	TMP	_	_
37	,	_	,	_	_	30	P	_	_
38	to	_	TO	_	_	28	ADV	_	_
39	Nov.	_	NNP	_	_	38	PMOD	_	_
40	6	_	CD	_	_	39	NMOD	_	_
41	.	_	.	_	_	25	P	_	_

1	A	_	DT	_	_	4	NMOD	_	_
2	C$	_	$	_	_	4	NMOD	_	_
3	30-a-share	_	JJ	_	_	2	AMOD	_	_
4	bid	_	NN	_	_	27	SBJ	_	_
5	by	_	IN	_	_	4	NMOD	_	_
6	Ciba-Geigy	_	NNP	_	_	5	PMOD	_	_
7	Ltd.	_	NNP	_	_	6	POSTHON	_	_
8	,	_	,	_	_	6	P	_	_
9	a	_	DT	_	_	11	NMOD	_	_
10	pharmaceutical	_	JJ	_	_	11	NMOD	_	_
11	company	_	NN	_	_	6	APPO	_	_
12	based	_	VBN	_	_	11	APPO	_	_
13	in	_	IN	_	_	12	LOC	_	_
14	Basel	_	NNP	_	_	13	PMOD	_	_
15	,	_	,	_	_	14	P	_	_
16	Switzerland	_	NNP	_	_	14	APPO	_	_
17	,	_	,	_	_	6	P	_	_
18	and	_	CC	_	_	6	COORD	_	_
19	California-based	_	JJ	_	_	20	NMOD	_	_
20	Chiron	_	NNP	_	_	18	CONJ	_	_
21	Corp.	_	NNP	_	_	20	POSTHON	_	_
22	,	_	,	_	_	20	P	_	_
23	a	_	DT	_	_	25	NMOD	_	_
24	bioresearch	_	NN	_	_	25	NMOD	_	_
25	concern	_	NN	_	_	20	APPO	_	_
26	,	_	,	_	_	20	P	_	_
27	was	_	VBD	_	_	0	ROOT	_	_
28	extended	_	VBN	_	_	27	VC	_	_
29	to	_	TO	_	_	28	ADV	_	_
30	Nov.	_	NNP	_	_	29	PMOD	_	_
31	16	_	CD	_	_	30	NMOD	_	_
32	.	_	.	_	_	27	P	_	_

1	It	_	PRP	_	_	2	SBJ	_	_
2	had	_	VBD	_	_	0	ROOT	_	_
3	been	_	VBN	_	_	2	VC	_	_
4	due	_	JJ	_	_	3	PRD	_	_
5	to	_	TO	_	_	4	AMOD	_	_
6	expire	_	VB	_	_	5	IM	_	_
7	Friday	_	NNP	_	_	8	NMOD	_	_
8	evening	_	NN	_	_	6	TMP	_	_
9	.	_	.	_	_	2	P	_	_

1	Merieux	_	NNP	_	_	3	SBJ	_	_
2	previously	_	RB	_	_	3	TMP	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	it	_	PRP	_	_	5	SBJ	_	_
5	would	_	MD	_	_	3	OBJ	_	_
6	ensure	_	VB	_	_	5	VC	_	_
7	its	_	PRP$	_	_	8	NMOD	_	_
8	bid	_	NN	_	_	9	SBJ	_	_
9	remained	_	VBD	_	_	6	OBJ	_	_
10	open	_	JJ	_	_	9	PRD	_	_
11	pending	_	VBG	_	_	9	ADV	_	_
12	a	_	DT	_	_	14	NMOD	_	_
13	final	_	JJ	_	_	14	NMOD	_	_
14	decision	_	NN	_	_	11	PMOD	_	_
15	by	_	IN	_	_	14	NMOD	_	_
16	Canadian	_	JJ	_	_	17	NMOD	_	_
17	regulators	_	NNS	_	_	15	PMOD	_	_
18	on	_	IN	_	_	14	NMOD	_	_
19	whether	_	IN	_	_	18	PMOD	_	_
20	to	_	TO	_	_	19	SUB	_	_
21	approve	_	VB	_	_	20	IM	_	_
22	the	_	DT	_	_	23	NMOD	_	_
23	takeover	_	NN	_	_	21	OBJ	_	_
24	.	_	.	_	_	3	P	_	_

1	Merieux	_	NNP	_	_	14	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	a	_	DT	_	_	4	NMOD	_	_
4	vaccine	_	NN	_	_	1	APPO	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	bioresearch	_	NN	_	_	7	NMOD	_	_
7	firm	_	NN	_	_	5	CONJ	_	_
8	based	_	VBN	_	_	4	APPO	_	_
9	in	_	IN	_	_	8	LOC	_	_
10	Lyon	_	NNP	_	_	9	PMOD	_	_
11	,	_	,	_	_	10	P	_	_
12	France	_	NNP	_	_	10	APPO	_	_
13	,	_	,	_	_	1	P	_	_
14	is	_	VBZ	_	_	0	ROOT	_	_
15	controlled	_	VBN	_	_	14	VC	_	_
16	50.1	_	CD	_	_	17	NMOD	_	_
17	%	_	NN	_	_	15	ADV	_	_
18	by	_	IN	_	_	15	LGS	_	_
19	state-owned	_	JJ	_	_	21	NMOD	_	_
20	Rhone	_	NNP	_	_	21	NAME	_	_
21	Poulenc	_	NNP	_	_	18	PMOD	_	_
22	S.A	_	NNP	_	_	21	POSTHON	_	_
23	.	_	.	_	_	14	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	Canadian	_	JJ	_	_	3	NMOD	_	_
3	government	_	NN	_	_	5	SBJ	_	_
4	previously	_	RB	_	_	5	TMP	_	_
5	said	_	VBD	_	_	0	ROOT	_	_
6	Merieux	_	NNP	_	_	8	NMOD	_	_
7	's	_	POS	_	_	6	SUFFIX	_	_
8	bid	_	NN	_	_	9	SBJ	_	_
9	did	_	VBD	_	_	5	OBJ	_	_
10	n't	_	RB	_	_	9	ADV	_	_
11	offer	_	VB	_	_	9	VC	_	_
12	enough	_	RB	_	_	15	NMOD	_	_
13	``	_	``	_	_	15	P	_	_
14	net	_	JJ	_	_	15	NMOD	_	_
15	benefit	_	NN	_	_	11	OBJ	_	_
16	''	_	''	_	_	15	P	_	_
17	to	_	TO	_	_	11	ADV	_	_
18	Canada	_	NNP	_	_	17	PMOD	_	_
19	to	_	TO	_	_	11	PRP	_	_
20	be	_	VB	_	_	19	IM	_	_
21	approved	_	VBN	_	_	20	VC	_	_
22	,	_	,	_	_	11	P	_	_
23	and	_	CC	_	_	11	COORD	_	_
24	gave	_	VBD	_	_	23	CONJ	_	_
25	Merieux	_	NNP	_	_	24	OBJ	_	_
26	an	_	DT	_	_	28	NMOD	_	_
27	until	_	IN	_	_	28	DEP	_	_
28	mid-November	_	NNP	_	_	24	OBJ	_	_
29	to	_	TO	_	_	24	PRP	_	_
30	submit	_	VB	_	_	29	IM	_	_
31	additional	_	JJ	_	_	32	NMOD	_	_
32	information	_	NN	_	_	30	OBJ	_	_
33	.	_	.	_	_	5	P	_	_

1	Merieux	_	NNP	_	_	2	NMOD	_	_
2	officials	_	NNS	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	last	_	JJ	_	_	5	NMOD	_	_
5	week	_	NN	_	_	3	TMP	_	_
6	that	_	IN	_	_	3	OBJ	_	_
7	they	_	PRP	_	_	8	SBJ	_	_
8	are	_	VBP	_	_	6	SUB	_	_
9	``	_	``	_	_	11	P	_	_
10	highly	_	RB	_	_	11	AMOD	_	_
11	confident	_	JJ	_	_	8	PRD	_	_
12	''	_	''	_	_	11	P	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	offer	_	NN	_	_	15	SBJ	_	_
15	will	_	MD	_	_	11	AMOD	_	_
16	be	_	VB	_	_	15	VC	_	_
17	approved	_	VBN	_	_	16	VC	_	_
18	once	_	IN	_	_	17	TMP	_	_
19	it	_	PRP	_	_	20	SBJ	_	_
20	submits	_	VBZ	_	_	18	SUB	_	_
21	details	_	NNS	_	_	20	OBJ	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	its	_	PRP$	_	_	25	NMOD	_	_
24	proposed	_	VBN	_	_	25	NMOD	_	_
25	investments	_	NNS	_	_	22	PMOD	_	_
26	to	_	TO	_	_	20	ADV	_	_
27	federal	_	JJ	_	_	28	NMOD	_	_
28	regulators	_	NNS	_	_	26	PMOD	_	_
29	.	_	.	_	_	3	P	_	_

1	Both	_	DT	_	_	2	NMOD	_	_
2	offers	_	NNS	_	_	3	SBJ	_	_
3	are	_	VBP	_	_	0	ROOT	_	_
4	conditional	_	JJ	_	_	3	PRD	_	_
5	on	_	IN	_	_	4	AMOD	_	_
6	regulatory	_	JJ	_	_	7	NMOD	_	_
7	approvals	_	NNS	_	_	5	PMOD	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	enough	_	JJ	_	_	10	NMOD	_	_
10	shares	_	NNS	_	_	11	SBJ	_	_
11	being	_	VBG	_	_	8	CONJ	_	_
12	tendered	_	VBN	_	_	11	VC	_	_
13	to	_	TO	_	_	12	PRP	_	_
14	give	_	VB	_	_	13	IM	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	bidders	_	NNS	_	_	14	OBJ	_	_
17	a	_	DT	_	_	18	NMOD	_	_
18	majority	_	NN	_	_	14	OBJ	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	Connaught	_	NNP	_	_	22	NMOD	_	_
21	's	_	POS	_	_	20	SUFFIX	_	_
22	shares	_	NNS	_	_	19	PMOD	_	_
23	outstanding	_	JJ	_	_	22	APPO	_	_
24	.	_	.	_	_	3	P	_	_

1	Institut	_	NNP	_	_	2	NAME	_	_
2	Merieux	_	NNP	_	_	14	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	which	_	WDT	_	_	6	SBJ	_	_
5	already	_	RB	_	_	6	TMP	_	_
6	holds	_	VBZ	_	_	2	NMOD	_	_
7	a	_	DT	_	_	10	NMOD	_	_
8	12.5	_	CD	_	_	9	AMOD	_	_
9	%	_	NN	_	_	10	NMOD	_	_
10	stake	_	NN	_	_	6	OBJ	_	_
11	in	_	IN	_	_	10	NMOD	_	_
12	Connaught	_	NNP	_	_	11	PMOD	_	_
13	,	_	,	_	_	2	P	_	_
14	said	_	VBD	_	_	0	ROOT	_	_
15	that	_	IN	_	_	14	OBJ	_	_
16	at	_	IN	_	_	42	TMP	_	_
17	the	_	DT	_	_	18	NMOD	_	_
18	close	_	NN	_	_	16	PMOD	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	business	_	NN	_	_	19	PMOD	_	_
21	Thursday	_	NNP	_	_	42	TMP	_	_
22	,	_	,	_	_	42	P	_	_
23	5,745,188	_	CD	_	_	24	NMOD	_	_
24	shares	_	NNS	_	_	42	SBJ	_	_
25	of	_	IN	_	_	24	NMOD	_	_
26	Connaught	_	NNP	_	_	25	PMOD	_	_
27	and	_	CC	_	_	24	COORD	_	_
28	C$	_	$	_	_	32	NMOD	_	_
29	44.3	_	CD	_	_	28	DEP	_	_
30	million	_	CD	_	_	28	DEP	_	_
31	face	_	NN	_	_	32	NMOD	_	_
32	amount	_	NN	_	_	27	CONJ	_	_
33	of	_	IN	_	_	32	NMOD	_	_
34	debentures	_	NNS	_	_	33	PMOD	_	_
35	,	_	,	_	_	32	P	_	_
36	convertible	_	JJ	_	_	32	APPO	_	_
37	into	_	IN	_	_	36	AMOD	_	_
38	1,826,596	_	CD	_	_	40	NMOD	_	_
39	common	_	JJ	_	_	40	NMOD	_	_
40	shares	_	NNS	_	_	37	PMOD	_	_
41	,	_	,	_	_	32	P	_	_
42	had	_	VBD	_	_	15	SUB	_	_
43	been	_	VBN	_	_	42	VC	_	_
44	tendered	_	VBN	_	_	43	VC	_	_
45	to	_	TO	_	_	44	ADV	_	_
46	its	_	PRP$	_	_	47	NMOD	_	_
47	offer	_	NN	_	_	45	PMOD	_	_
48	.	_	.	_	_	14	P	_	_

1	At	_	IN	_	_	11	TMP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	close	_	NN	_	_	1	PMOD	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	business	_	NN	_	_	4	PMOD	_	_
6	Thursday	_	NNP	_	_	11	TMP	_	_
7	,	_	,	_	_	11	P	_	_
8	Ciba-Geigy	_	NNP	_	_	11	SBJ	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	Chiron	_	NNP	_	_	9	CONJ	_	_
11	said	_	VBD	_	_	0	ROOT	_	_
12	11,580	_	CD	_	_	14	NMOD	_	_
13	common	_	JJ	_	_	14	NMOD	_	_
14	shares	_	NNS	_	_	15	SBJ	_	_
15	had	_	VBD	_	_	11	OBJ	_	_
16	been	_	VBN	_	_	15	VC	_	_
17	tendered	_	VBN	_	_	16	VC	_	_
18	to	_	TO	_	_	17	ADV	_	_
19	their	_	PRP$	_	_	20	NMOD	_	_
20	offer	_	NN	_	_	18	PMOD	_	_
21	.	_	.	_	_	11	P	_	_

1	At	_	IN	_	_	6	TMP	_	_
2	last	_	JJ	_	_	3	NMOD	_	_
3	report	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	6	P	_	_
5	Connaught	_	NNP	_	_	6	SBJ	_	_
6	had	_	VBD	_	_	0	ROOT	_	_
7	21.8	_	CD	_	_	8	DEP	_	_
8	million	_	CD	_	_	9	NMOD	_	_
9	shares	_	NNS	_	_	6	OBJ	_	_
10	outstanding	_	JJ	_	_	9	APPO	_	_
11	.	_	.	_	_	6	P	_	_

1	Separately	_	RB	_	_	7	ADV	_	_
2	,	_	,	_	_	7	P	_	_
3	the	_	DT	_	_	6	NMOD	_	_
4	Ontario	_	NNP	_	_	6	NAME	_	_
5	Supreme	_	NNP	_	_	6	NAME	_	_
6	Court	_	NNP	_	_	7	SBJ	_	_
7	said	_	VBD	_	_	0	ROOT	_	_
8	it	_	PRP	_	_	9	SBJ	_	_
9	will	_	MD	_	_	7	OBJ	_	_
10	postpone	_	VB	_	_	9	VC	_	_
11	indefinitely	_	RB	_	_	10	TMP	_	_
12	a	_	DT	_	_	13	NMOD	_	_
13	ruling	_	NN	_	_	10	OBJ	_	_
14	on	_	IN	_	_	13	NMOD	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	lawsuit	_	NN	_	_	14	PMOD	_	_
17	launched	_	VBN	_	_	16	APPO	_	_
18	by	_	IN	_	_	17	LGS	_	_
19	the	_	DT	_	_	20	NMOD	_	_
20	University	_	NNP	_	_	18	PMOD	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	Toronto	_	NNP	_	_	21	PMOD	_	_
23	against	_	IN	_	_	17	ADV	_	_
24	Connaught	_	NNP	_	_	23	PMOD	_	_
25	in	_	IN	_	_	17	ADV	_	_
26	connection	_	NN	_	_	25	PMOD	_	_
27	with	_	IN	_	_	26	NMOD	_	_
28	the	_	DT	_	_	30	NMOD	_	_
29	Merieux	_	NNP	_	_	30	NMOD	_	_
30	bid	_	NN	_	_	27	PMOD	_	_
31	.	_	.	_	_	7	P	_	_

1	In	_	IN	_	_	15	LOC	_	_
2	a	_	DT	_	_	3	NMOD	_	_
3	statement	_	NN	_	_	1	PMOD	_	_
4	prepared	_	VBN	_	_	3	APPO	_	_
5	by	_	IN	_	_	4	LGS	_	_
6	lawyers	_	NNS	_	_	5	PMOD	_	_
7	for	_	IN	_	_	4	ADV	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	university	_	NN	_	_	7	PMOD	_	_
10	and	_	CC	_	_	9	COORD	_	_
11	Connaught	_	NNP	_	_	10	CONJ	_	_
12	,	_	,	_	_	15	P	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	parties	_	NNS	_	_	15	SBJ	_	_
15	said	_	VBD	_	_	0	ROOT	_	_
16	they	_	PRP	_	_	17	SBJ	_	_
17	agreed	_	VBD	_	_	15	OBJ	_	_
18	that	_	IN	_	_	17	OBJ	_	_
19	as	_	IN	_	_	33	PRP	_	_
20	a	_	DT	_	_	21	NMOD	_	_
21	result	_	NN	_	_	19	PMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	reaching	_	VBG	_	_	22	PMOD	_	_
24	a	_	DT	_	_	29	NMOD	_	_
25	C	_	$	_	_	29	NMOD	_	_
26	415	_	CD	_	_	25	DEP	_	_
27	million	_	CD	_	_	25	DEP	_	_
28	research	_	NN	_	_	29	NMOD	_	_
29	accord	_	NN	_	_	23	OBJ	_	_
30	,	_	,	_	_	33	P	_	_
31	``	_	``	_	_	33	P	_	_
32	It	_	PRP	_	_	33	SBJ	_	_
33	is	_	VBZ	_	_	18	SUB	_	_
34	unnecessary	_	JJ	_	_	33	PRD	_	_
35	that	_	IN	_	_	33	EXTR	_	_
36	there	_	EX	_	_	37	SBJ	_	_
37	be	_	VB	_	_	35	SUB	_	_
38	a	_	DT	_	_	39	NMOD	_	_
39	judgment	_	NN	_	_	37	PRD	_	_
40	on	_	IN	_	_	39	NMOD	_	_
41	the	_	DT	_	_	42	NMOD	_	_
42	merits	_	NNS	_	_	40	PMOD	_	_
43	{	_	(	_	_	42	P	_	_
44	of	_	IN	_	_	42	NMOD	_	_
45	the	_	DT	_	_	46	NMOD	_	_
46	case	_	NN	_	_	44	PMOD	_	_
47	}	_	)	_	_	42	P	_	_
48	at	_	IN	_	_	37	TMP	_	_
49	this	_	DT	_	_	50	NMOD	_	_
50	time	_	NN	_	_	48	PMOD	_	_
51	.	_	.	_	_	15	P	_	_
52	''	_	''	_	_	15	P	_	_

1	Lawyers	_	NNS	_	_	6	SBJ	_	_
2	for	_	IN	_	_	1	NMOD	_	_
3	the	_	DT	_	_	5	NMOD	_	_
4	two	_	CD	_	_	5	NMOD	_	_
5	sides	_	NNS	_	_	2	PMOD	_	_
6	were	_	VBD	_	_	0	ROOT	_	_
7	n't	_	RB	_	_	6	ADV	_	_
8	immediately	_	RB	_	_	6	TMP	_	_
9	available	_	JJ	_	_	6	PRD	_	_
10	for	_	IN	_	_	9	AMOD	_	_
11	comment	_	NN	_	_	10	PMOD	_	_
12	.	_	.	_	_	6	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	university	_	NN	_	_	3	SBJ	_	_
3	had	_	VBD	_	_	0	ROOT	_	_
4	sought	_	VBN	_	_	3	VC	_	_
5	an	_	DT	_	_	6	NMOD	_	_
6	injunction	_	NN	_	_	4	OBJ	_	_
7	blocking	_	VBG	_	_	6	APPO	_	_
8	Connaught	_	NNP	_	_	10	NMOD	_	_
9	's	_	POS	_	_	8	SUFFIX	_	_
10	board	_	NN	_	_	7	OBJ	_	_
11	from	_	IN	_	_	7	ADV	_	_
12	recommending	_	VBG	_	_	11	PMOD	_	_
13	or	_	CC	_	_	12	COORD	_	_
14	supporting	_	VBG	_	_	13	CONJ	_	_
15	an	_	DT	_	_	16	NMOD	_	_
16	offer	_	NN	_	_	12	OBJ	_	_
17	for	_	IN	_	_	16	NMOD	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	company	_	NN	_	_	17	PMOD	_	_
20	by	_	IN	_	_	16	NMOD	_	_
21	Merieux	_	NNP	_	_	20	PMOD	_	_
22	.	_	.	_	_	3	P	_	_

